Silybin suppresses ovarian cancer cell proliferation by inhibiting isocitrate dehydrogenase 1 activity

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• Metabolic reprogramming is a hallmark of cancer, making tumor cell metabolism a therapeutic target.
• Silybin, a flavonoid known for liver protection, demonstrates significant anti-tumor properties.
• Ovarian cancer is a major health concern, necessitating novel therapeutic strategies.

Purpose of the Study:

• To investigate the anti-tumor effects of Silybin on human ovarian cancer cells.
• To identify the molecular target of Silybin in ovarian cancer.
• To evaluate Silybin's therapeutic potential in preclinical models.

Main Methods:

• Drug affinity responsive target stability (DARTS) assay to identify Silybin's binding protein.
• Enzyme activity assays to assess the effect of Silybin on target protein function.
• Immunohistochemistry to analyze target protein expression in patient samples.
• Xenograft mouse models to evaluate Silybin's efficacy in vivo.

Main Results:

• Silybin treatment disrupted glutamine metabolism and the tricarboxylic acid cycle in ovarian cancer cells.
• Silybin was identified as a binder of isocitrate dehydrogenase 1 (IDH1).
• Silybin inhibited IDH1 activity by reducing its phosphorylation, leading to increased reactive oxygen species.
• IDH1 expression was elevated in ovarian tumors compared to normal tissues.
• Oral administration of Silybin suppressed tumor growth in a murine xenograft model.

Conclusions:

• Silybin targets and inhibits IDH1 in ovarian cancer cells.
• Silybin's mechanism involves metabolic disruption and oxidative stress induction.
• Silybin shows promise as a novel therapeutic agent for ovarian cancer.